FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paul Schellhammer

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Anatomy

Prostate

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Maha Hussain; Subramanian Kanaga Sundaram; Glenn Liu; Carol M Moinpour; Stephen Prescott; David I Quinn; Derek Raghavan; Paul F Schellhammer; Eric Jay Small; Catherine M Tangen; Donna L Berry; E David Crawford; Nancy Ann Dawson; Bryan J Donnelly; Benjamin Ely; Celestia S Higano; Ulka N Vaishampayan; Peter M Venner; Nicholas J Vogelzang; George Wilding; Ian M Thompson
Intermittent versus continuous androgen deprivation in prostate cancer.
Paul F Schellhammer
Treater to target: a urologist's personal experience with prostate cancer.
Juanita M Crook; David P Dearnaley; Keyue Ding; Graeme Duncan; Eliot Frymire; S Larry Goldenberg; Mary K Gospodarowicz; Emma Hall; Celestia S Higano; Eric M Horwitz; John P Logue; Shawn Malone; Abdenour Nabid; Christopher J O'Callaghan; Fred Saad; Paul F Schellhammer; Padraig Warde; Steve Angyalfi; Joseph Chin; Thomas Corbett; Laurence Klotz
Intermittent androgen suppression for rising PSA level after radiotherapy.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paul Schellhammer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Maha Hussain; Subramanian Kanaga Sundaram; Glenn Liu; Carol M Moinpour; Stephen Prescott; David I Quinn; Derek Raghavan; Paul F Schellhammer; Eric Jay Small; Catherine M Tangen; Donna L Berry; E David Crawford; Nancy Ann Dawson; Bryan J Donnelly; Benjamin Ely; Celestia S Higano; Ulka N Vaishampayan; Peter M Venner; Nicholas J Vogelzang; George Wilding; Ian M Thompson
Intermittent versus continuous androgen deprivation in prostate cancer.
The New England journal of medicine 2013;368(14):1314-25.
2012: Paul F Schellhammer
Treater to target: a urologist's personal experience with prostate cancer.
Journal of the National Cancer Institute. Monographs 2012;2012(45):143-5.
2012: Juanita M Crook; David P Dearnaley; Keyue Ding; Graeme Duncan; Eliot Frymire; S Larry Goldenberg; Mary K Gospodarowicz; Emma Hall; Celestia S Higano; Eric M Horwitz; John P Logue; Shawn Malone; Abdenour Nabid; Christopher J O'Callaghan; Fred Saad; Paul F Schellhammer; Padraig Warde; Steve Angyalfi; Joseph Chin; Thomas Corbett; Laurence Klotz
Intermittent androgen suppression for rising PSA level after radiotherapy.
The New England journal of medicine 2012;367(10):895-903.
2012: Philip W Kantoff; Mark W Frohlich; Celestia S Higano; Eric J Small; James B Whitmore; Paul F Schellhammer
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer.
Journal of the National Cancer Institute 2012;104(14):1107-9; author reply 1109-12.
2011: Ravinder Mohan; Paul F Schellhammer
Treatment options for localized prostate cancer.
American family physician 2011;84(4):413-20.
2011: Tomasz M Beer; Guy T Bernstein; John M Corman; L Michael Glode; Simon J Hall; Lori A Jones; Jelle W Kylstra; Wayne L Poll; Paul F Schellhammer; Yi Xu; Mark W Frohlich
Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4558-67.
2011: Paul F Schellhammer
Editorial comment.
The Journal of urology 2011;185(3):854; author reply 854.
2010: Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
The New England journal of medicine 2010;363(5):411-22.
2010: John B Malcolm; Michael D Fabrizio; Bethany B Barone; Robert W Given; Raymond S Lance; Donald F Lynch; John W Davis; Mark E Shaves; Paul F Schellhammer
Quality of life after open or robotic prostatectomy, cryoablation or brachytherapy for localized prostate cancer.
The Journal of urology 2010;183(5):1822-8.
2010: Paul F Schellhammer
Re: Chemoprevention of prostate cancer. I. M. Thompson, C. M. Tangen, P. J. Goodman, M. S. Lucia and E. A. Klein. J Urol 2009; 182: 499-508.
The Journal of urology 2010;183(3):1258-9; author reply 1259.
2010: Oliver Sartor; David G McLeod; Susan Halabi; Paul F Schellhammer; Peter T Scardino; Anthony V D'Amico; Charles Bennett; John T Wei
The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer.
Urology 2010;75(3):623-9.
2009: Celestia S Higano; Paul F Schellhammer; Eric J Small; Patrick A Burch; John Nemunaitis; Lianng Yuh; Nicole Provost; Mark W Frohlich
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
Cancer 2009;115(16):3670-9.
2009: Paul F Schellhammer
Words of wisdom. Re: Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.
European urology 2009;55(2):522-3.
2009: Krista Y White; Lucy Rodemich; Julius Nyalwidhe; Mary Ann Comunale; Mary Ann Clements; Raymond S Lance; Paul F Schellhammer; Anand S Mehta; O John Semmes; Richard R Drake
Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids.
Journal of proteome research 2009;8(2):620-30.
2008: Christopher J Logothetis; Paul F Schellhammer
High-grade prostate cancer and the prostate cancer prevention trial.
Cancer prevention research (Philadelphia, Pa.) 2008;1(3):151-2.
2007: Scott G Hubosky; Michael D Fabrizio; Paul F Schellhammer; Bethany B Barone; Christopher M Tepera; Robert W Given
Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
Journal of endourology / Endourological Society 2007;21(12):1521-31.
2007: Jose I Diaz; Alberto Corica; R McKenzie; Paul F Schellhammer
[Comparative study of surgical efficacy in open versus laparoscopic prostatectomy: virtual prostate reconstruction and periprostatic tissue quantification].
Actas urologicas españolas 2007;31(9):1045-55.
2007: Paul F Schellhammer; Jose I Diaz; Michael D Fabrizio; John W Davis; Robert W Given; Brian Main; N Rao Chaganty; Rania Hussein; Rick McKenzie
Computer modeling technology to assess extracapsular tissue coverage of whole mount sections after retropubic and laparoscopic radical prostatectomy.
The Journal of urology 2007;178(4 Pt 1):1301-5.
2007: Jonathan Harris Taylor; John Davis; Paul F Schellhammer
Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
Clinical genitourinary cancer 2007;5(6):386-9.
2006: Adam J Ball; Bethany Gambill; Michael D Fabrizio; John W Davis; Robert W Given; Donald F Lynch; Mark E Shaves; Paul F Schellhammer
Prospective longitudinal comparative study of early health-related quality-of-life outcomes in patients undergoing surgical treatment for localized prostate cancer: a short-term evaluation of five approaches from a single institution.
Journal of endourology / Endourological Society 2006;20(10):723-31.
2006: Eric J Small; Paul F Schellhammer; Celestia S Higano; Charles H Redfern; John Nemunaitis; Frank H Valone; Suleman S Verjee; Lori A Jones; Robert M Hershberg
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(19):3089-94.
2006: Daniel A Holterman; Jose I Diaz; Peter F Blackmore; John W Davis; Paul F Schellhammer; Alberto Corica; O John Semmes; Antonia Vlahou
Overexpression of alpha-defensin is associated with bladder cancer invasiveness.
Urologic oncology 2006;24(2):97-108.
2005: Michael F Sarosdy; Catherine M Tangen; Geoffrey R Weiss; Blake R Nestok; Mitchell C Benson; Paul F Schellhammer; Arthur I Sagalowsky; David P Wood Jr; E David Crawford
A phase II clinical trial of oral bropirimine in combination with intravesical bacillus Calmette-Guérin for carcinoma in situ of the bladder: a Southwest Oncology Group Study.
Urologic oncology 2005;23(6):386-9.
2005: Douglas W Soderdahl; Jose I Diaz; Danny M Rabah; Paul F Schellhammer; Michael D Fabrizio
Laparoscopic radical prostatectomy: evaluation of specimen pathologic features to critically assess and modify surgical technique.
Urology 2005;66(3):552-6.
2005: Douglas W Soderdahl; John W Davis; Paul F Schellhammer; Robert W Given; Donald F Lynch; Mark E Shaves; Bonnie L Burke; Michael D Fabrizio
Prospective longitudinal comparative study of health-related quality of life in patients undergoing invasive treatments for localized prostate cancer.
Journal of endourology / Endourological Society 2005;19(3):318-26.
2005: Paul F Schellhammer; Robert M Hershberg
Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer.
World journal of urology 2005;23(1):47-9.
2004: Danny M Rabah; Paul F Schellhammer; Jose I Diaz; Ingolf Tuerk; Douglas W Soderdahl; Michael D Fabrizio
Laparoscopic radical prostatectomy: is intact organ removal attainable? Study of margin status.
Journal of endourology / Endourological Society 2004;18(8):731-4.
2004: Antonia Vlahou; Aris Giannopoulos; Betsy Gregory; Theodoros Manousakas; Filippos I Kondylis; Lori L Wilson; Paul F Schellhammer; George L Wright; O John Semmes
Protein profiling in urine for the diagnosis of bladder cancer.
Clinical chemistry 2004;50(8):1438-41.
2004: John W Davis; Mark E Shaves; Paul F Schellhammer
Contemporary management of prostate cancer with lethal potential.
Oncology (Williston Park, N.Y.) 2004;18(7):811-20; discussion 820-4, 829-32.
2004: Paul F Schellhammer; John W Davis
An evaluation of bicalutamide in the treatment of prostate cancer.
Clinical prostate cancer 2004;2(4):213-9.
2004: Richard P Ciavarra; Daniel A Holterman; Roy R Brown; Patricia Mangiotti; Nazita Yousefieh; George L Wright; Paul F Schellhammer; William F Glass; Kenneth D Somers
Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2004;27(1):13-26.
2003: Kenneth D Somers; Roy R Brown; Daniel A Holterman; Nazita Yousefieh; William F Glass; George L Wright; Paul F Schellhammer; Jesse Qian; Richard P Ciavarra
Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: efficacy of flt3 ligand immunotherapy.
International journal of cancer. Journal international du cancer 2003;107(5):773-80.
2003: Filippos I Kondylis; Richard P Moriarty; David Bostwick; Paul F Schellhammer
Prostate cancer grade assignment: the effect of chronological, interpretive and translation bias.
The Journal of urology 2003;170(4 Pt 1):1189-93.
2003: Richard P Ciavarra; Roy R Brown; Daniel A Holterman; Marianne Garrett; William F Glass; George L Wright; Paul F Schellhammer; Kenneth D Somers
Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer.
Cancer immunology, immunotherapy : CII 2003;52(9):535-45.
2003: Paul F Schellhammer
Clinical trials in prostate cancer.
BJU international 2003;92(3):186-7.
2003: Michael D Fabrizio; Ingolf Tuerk; Paul F Schellhammer
Laparoscopic radical prostatectomy: decreasing the learning curve using a mentor initiated approach.
The Journal of urology 2003;169(6):2063-5.
2003: Yinsheng Qu; Bao-Ling Adam; Mark D Thornquist; John D Potter; Mary Lou Thompson; Yutaka Yasui; John Davis; Paul F Schellhammer; Lisa H Cazares; MaryAnn Clements; George L Wright; Ziding Feng
Data reduction using a discrete wavelet transform in discriminant analysis of very high dimensionality data.
Biometrics 2003;59(1):143-51.
2003: Antonia Vlahou; Paul F Schellhammer; George L Wright
Application of a novel protein chip mass spectrometry technology for the identification of bladder cancer-associated biomarkers.
Advances in experimental medicine and biology 2003;539(Pt A):47-60.
2002: Michael B Pryor; Paul F Schellhammer
The pursuit of prostate cancer in patients with a rising prostate-specific antigen and multiple negative transrectal ultrasound-guided prostate biopsies.
Clinical prostate cancer 2002;1(3):172-6.
2002: Michael F Sarosdy; Paul F Schellhammer; Gary Bokinsky; Paul Kahn; Roberto Chao; Lawrence Yore; Joseph Zadra; Daniel Burzon; Gerald Osher; Julia A Bridge; Steven Anderson; Sonny L Johansson; Michael Lieber; Mark S Soloway; Kerry Flom
Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer.
The Journal of urology 2002;168(5):1950-4.
2002: Yinsheng Qu; Bao-Ling Adam; Yutaka Yasui; Michael D Ward; Lisa H Cazares; Paul F Schellhammer; Ziding Feng; O John Semmes; George L Wright
Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients.
Clinical chemistry 2002;48(10):1835-43.
2002: Ingolf Arthur Turk; Serdar Deger; William Ritchie Morgan; John Warren Davis; Paul F Schellhammer; Stefan A Loening
Sural nerve graft during laparoscopic radical prostatectomy. Initial experience.
Urologic oncology 2002;7(5):191-4.
2002: Paul F Schellhammer
An evaluation of bicalutamide in the treatment of prostate cancer.
Expert opinion on pharmacotherapy 2002;3(9):1313-28.
2002: Lisa H Cazares; Bao-Ling Adam; Michael D Ward; Suhail Nasim; Paul F Schellhammer; O John Semmes; George L Wright
Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(8):2541-52.
2002: Bao-Ling Adam; Yinsheng Qu; John W Davis; Michael D Ward; Mary Ann Clements; Lisa H Cazares; O John Semmes; Paul F Schellhammer; Yutaka Yasui; Ziding Feng; George L Wright
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men.
Cancer research 2002;62(13):3609-14.
2002: John W Davis; Seemit I Sheth; Michael J Doviak; Paul F Schellhammer
Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup.
The Journal of urology 2002;167(2 Pt 1):494-500; discussion 501.
2001: John W Davis; DA Kuban; Donald F Lynch; Paul F Schellhammer
Quality of life after treatment for localized prostate cancer: differences based on treatment modality.
The Journal of urology 2001;166(3):947-52.
2001: Z Xiao; Bao-Ling Adam; Lisa H Cazares; Mary Ann Clements; John W Davis; Paul F Schellhammer; Enrique A Dalmasso; George L Wright
Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease.
Cancer research 2001;61(16):6029-33.
2001: Paul F Schellhammer
Luteinizing hormone-releasing hormone monotherapy: a viable option for treatment of prostate cancer?
Urology 2001;58(2 Suppl 1):10-5.
2001: Antonia Vlahou; Paul F Schellhammer; S Mendrinos; K Patel; Filippos I Kondylis; L Gong; S Nasim; G L Wright Jr
Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine.
The American journal of pathology 2001;158(4):1491-502.
2001: John W Davis; Richard P Moriarty; Steven M Schlossberg; Paul F Schellhammer
Bilateral testicular lymphoma treated with chemotherapy and radiation without orchiectomy: complete response relapsed at 52 months in the vitreous humor.
Urology 2001;57(3):555.
2001: P Carroll; C Coley; D McLeod; Paul F Schellhammer; G Sweat; J Wasson; A Zietman; Ian M Thompson
Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up.
Urology 2001;57(2):225-9.
2001: P Carroll; C Coley; D McLeod; Paul F Schellhammer; G Sweat; J Wasson; A Zietman; Ian M Thompson
Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer.
Urology 2001;57(2):217-24.
2001: John W Davis; Paul F Schellhammer
Prostatorectal fistula 14 years following brachytherapy for prostate cancer.
The Journal of urology 2001;165(1):189.
2000: L S Incognito; Lisa H Cazares; Paul F Schellhammer; D A Kuban; E O Van Dyk; Richard P Moriarty; George L Wright; Kenneth D Somers
Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy.
International journal of oncology 2000;17(4):761-9.
2000: Paul F Schellhammer; Richard P Moriarty; D Bostwick; D Kuban
Fifteen-year minimum follow-up of a prostate brachytherapy series: comparing the past with the present.
Urology 2000;56(3):436-9.
2000: Ralph W deVere White; Arline D Deitch; Siamak Daneshmand; Brent Blumenstein; Bruce A Lowe; A I Sagalowsky; J A Smith; Paul F Schellhammer; T H Stanisic; H Barton Grossman; E Messing; JD Crissman; E D Crawford
The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. A Southwest Oncology Group Study.
European urology 2000;37(5):595-600.
2000: Richard P Ciavarra; Kenneth D Somers; Roy R Brown; William F Glass; P J Consolvo; George L Wright; Paul F Schellhammer
Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer.
Cancer research 2000;60(8):2081-4.
2000: Filippos I Kondylis; S Demirci; L Ladaga; P Kolm; Paul F Schellhammer
Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transitional cell carcinoma.
The Journal of urology 2000;163(4):1120-3.
2000: Michael F Sarosdy; Paul F Schellhammer; R Johnson; K Carroll; GJ Kolvenbag
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
Urology 2000;55(3):391-5; discussion 395-6.
2000: George L Wright; ML Beckett; K R Newhall; Bao-Ling Adam; Lisa H Cazares; S L Cartwright; Z Xiao; L Gong; Paul F Schellhammer
Identification of a superimmunoglobulin gene family member overexpressed in benign prostatic hyperplasia .
The Prostate 2000;42(3):230-8.
1999: ML Beckett; Lisa H Cazares; Antonia Vlahou; Paul F Schellhammer; George L Wright
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4034-40.
1999: Kurt A McCammon; P Kolm; B Main; Paul F Schellhammer
Comparative quality-of-life analysis after radical prostatectomy or external beam radiation for localized prostate cancer.
Urology 1999;54(3):509-16.
1999: John W Davis; P Kolm; G L Wright; DA Kuban; AM el-Mahdi; Paul F Schellhammer
The durability of external beam radiation therapy for prostate cancer: can it be identified?
The Journal of urology 1999;162(3 Pt 1):758-61.
1999: David G McLeod; Paul F Schellhammer; Nicholas J Vogelzang; Mark S Soloway; Roohollah Sharifi; Norman Block; PM Venner; AL Patterson; Michael F Sarosdy; R P Kelley; GJ Kolvenbag
Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
The Prostate 1999;40(4):218-24.
1999: Michael F Sarosdy; Paul F Schellhammer; Mark S Soloway; Nicholas J Vogelzang; E David Crawford; J Presti; Gerald Chodak; P Mitchell; L Porter
Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer.
BJU international 1999;83(7):801-6.
1999: John W Davis; Paul F Schellhammer; Steven M Schlossberg
Conservative surgical therapy for penile and urethral carcinoma.
Urology 1999;53(2):386-92.
1998: Kurt A McCammon; A N Lentzner; Richard P Moriarty; Paul F Schellhammer
Intravesical dimethyl sulfoxide for primary amyloidosis of the bladder.
Urology 1998;52(6):1136-8.
1998: Paul F Schellhammer
Intravesical chemotherapy with gamma linolenic acid becomes a reality.
The Journal of urology 1998;160(6 Pt 1):1963.
1998: J Gresham; P Margiotta; AJ Palad; Kenneth D Somers; Peter F Blackmore; George L Wright; Paul F Schellhammer; WJ Wasilenko
Involvement of Shc in the signaling response of human prostate tumor cell lines to epidermal growth factor.
International journal of cancer. Journal international du cancer 1998;77(6):923-7.
1998: Michael F Sarosdy; Paul F Schellhammer; Roohollah Sharifi; Norman Block; Mark S Soloway; PM Venner; AL Patterson; Nicholas J Vogelzang; Gerald Chodak; Eric A Klein; J J Schellenger; GJ Kolvenbag
Comparison of goserelin and leuprolide in combined androgen blockade therapy.
Urology 1998;52(1):82-8.
1998: Paul F Schellhammer
What is the available evidence to support immediate adjuvant intravesical chemotherapy after transurethral resection of superficial transitional cell carcinoma of the bladder?
Urologic oncology 1998;4(3):73-9.
1998: DA Kuban; AM el-Mahdi; Paul F Schellhammer
PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it?
Seminars in radiation oncology 1998;8(2):72-80.
1997: Paul F Schellhammer; Donald F Lynch
Are monotherapy options reasonable for T3 prostate cancer?
Seminars in urologic oncology 1997;15(4):207-14.
1997: Michael F Sarosdy; M A Hudson; William J Ellis; Mark S Soloway; Ralph W deVere White; Joel Sheinfeld; M V Jarowenko; Paul F Schellhammer; E W Schervish; J V Patel; Gerald Chodak; D L Lamm; R D Johnson; M Henderson; Greg Adams; Brent Blumenstein; Kent Thoelke; R D Pfalzgraf; H A Murchison; S L Brunelle
Improved detection of recurrent bladder cancer using the Bard BTA stat Test.
Urology 1997;50(3):349-53.
1997: Paul F Schellhammer; Roohollah Sharifi; Norman Block; Mark S Soloway; PM Venner; AL Patterson; Michael F Sarosdy; Nicholas J Vogelzang; J J Schellenger; GJ Kolvenbag
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Urology 1997;50(3):330-6.
1997: Donald F Lynch; WALEED HASSEN; Mary Ann Clements; Paul F Schellhammer; George L Wright
Serum levels of endothelial and neural cell adhesion molecules in prostate cancer.
The Prostate 1997;32(3):214-20.
1997: John W Davis; Paul F Schellhammer
Collagen mass in prostatic bed after radical retropubic prostatectomy.
Urology 1997;50(1):121.
1997: T T Bui; Paul F Schellhammer
Additional bacillus Calmette-Guérin therapy for recurrent transitional cell carcinoma after an initial complete response.
Urology 1997;49(5):687-90; discussion 690-1.
1997: Paul F Schellhammer; AM el-Mahdi; DA Kuban; G L Wright
Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir.
The Urologic clinics of North America 1997;24(2):407-14.
1997: Paul F Schellhammer; PM Venner; Gabriel P Haas; E J Small; P T Nieh; D R Seabaugh; AL Patterson; E Klein; Zev Wajsman; BJ Furr; Y Chen; GJ Kolvenbag
Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.
The Journal of urology 1997;157(5):1731-5.
1997: Paul F Schellhammer; A Cockett; L Boccon-Gibod; M Gospodarowicz; A Krongrad; Ian M Thompson; Peter T Scardino; Mark S Soloway; J Adolfsson
Assessment of endpoints for clinical trials for localized prostate cancer.
Urology 1997;49(4A Suppl):27-38.
1997: WJ Wasilenko; J Cooper; AJ Palad; Kenneth D Somers; Peter F Blackmore; J S Rhim; George L Wright; Paul F Schellhammer
Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP.
The Prostate 1997;30(3):167-73.
1996: Paul F Schellhammer; Roohollah Sharifi; Norman Block; Mark S Soloway; PM Venner; AL Patterson; Michael F Sarosdy; Nicholas J Vogelzang; Y Chen; GJ Kolvenbag
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group.
Cancer 1996;78(10):2164-9.
1996: WJ Wasilenko; A J Palad; Kenneth D Somers; Peter F Blackmore; Elise C Kohn; J S Rhim; George L Wright; Paul F Schellhammer
Effects of the calcium influx inhibitor carboxyamido-triazole on the proliferation and invasiveness of human prostate tumor cell lines.
International journal of cancer. Journal international du cancer 1996;68(2):259-64.
1996: George L Wright; B M Grob; C Haley; K Grossman; K Newhall; D Petrylak; J Troyer; A Konchuba; Paul F Schellhammer; R Moriarty
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.
Urology 1996;48(2):326-34.
1996: Paul F Schellhammer
Combined androgen blockade for the treatment of metastatic cancer of the prostate.
Urology 1996;47(5):622-8.
1996: Ralph W deVere White; A D Deitch; H Tesluk; B Blumensteinj; B A Lowe; A I Sagalowsky; J A Smith; Paul F Schellhammer; T H Stanisic; H Barton Grossman; E Messing; JD Crissman; E D Crawford
Prognostic significance of DNA ploidy in Ta/Tl bladder cancer: A southwest oncology group study.
Urologic oncology 1996;2(1):27-34.
1996: Mark S Soloway; Paul F Schellhammer; Roohollah Sharifi; PM Venner; AL Patterson; Michael F Sarosdy; Nicholas J Vogelzang; J Jones; GJ Kolvenbag
A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.
European urology 1996;29 Suppl 2():105-9.
1996: Paul F Schellhammer; Roohollah Sharifi; Norman Block; Mark S Soloway; PM Venner; AL Patterson; Michael F Sarosdy; Nicholas J Vogelzang; J Jones; GJ Kolvenbag
Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Urology 1996;47(1A Suppl):54-60; discussion 80-4.
1995: S J Fabozzi; Paul F Schellhammer; AM el-Mahdi
Pulmonary metastases from prostate cancer.
Cancer 1995;75(11):2706-9.
1995: George L Wright; Paul F Schellhammer
Overview of contents.
Urologic oncology 1995;1(3):93-4.
1995: Paul F Schellhammer; Roohollah Sharifi; Norman Block; Mark S Soloway; PM Venner; AL Patterson; Michael F Sarosdy; Nicholas J Vogelzang; J Jones; GJ Kolvenbag
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
Urology 1995;45(5):745-52.
1995: DA Kuban; AM el-Mahdi; Paul F Schellhammer
Potential benefit of improved local tumor control in patients with prostate carcinoma.
Cancer 1995;75(9):2373-82.
1995: S J Fabozzi; P Kolm; Paul F Schellhammer
PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the antiandrogen casodex.
Urologic oncology 1995;1(2):64-6.
1995: Steven M Schlossberg; G Jordan; Paul F Schellhammer
Repair of obliterative vesicourethral stricture after radical prostatectomy: a technique for preservation of continence.
Urology 1995;45(3):510-3.
1995: S J Fabozzi; J R Newton; R P Moriarty; Paul F Schellhammer
Malignant pericardial effusion as initial solitary site of metastasis from transitional cell carcinoma of the bladder.
Urology 1995;45(2):320-2.
1995: George L Wright; C Haley; ML Beckett; Paul F Schellhammer
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.
Urologic oncology 1995;1(1):18-28.
1995: Paul F Schellhammer; L E Ladaga; R P Moriarty
Intravesical bacillus Calmette-Guerin for the treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder.
The Journal of urology 1995;153(1):53-6.
1994: B M Grob; Paul F Schellhammer; D N Brassil; George L Wright
Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer.
Urology 1994;44(4):525-9.
1993: Paul F Schellhammer; DA Kuban; AM el-Mahdi
Treatment of clinical local failure after radiation therapy for prostate carcinoma.
The Journal of urology 1993;150(6):1851-5.
1993: Paul F Schellhammer; G L Wright
Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers.
The Urologic clinics of North America 1993;20(4):597-606.
1993: E B Miller; G R Eure; Paul F Schellhammer
Upper tract transitional cell carcinoma following treatment of superficial bladder cancer with BCG.
Urology 1993;42(1):26-30.
1993: Paul F Schellhammer; AM el-Mahdi; George L Wright; P Kolm; R Ragle
Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate.
Urology 1993;42(1):13-20.
1993: A M Konchuba; Paul F Schellhammer; P Kolm; M A Clements; George L Wright
Deoxyribonucleic acid cytometric analysis of prostate core biopsy specimens: relationship to serum prostate specific antigen and prostatic acid phosphatase, clinical stage and histopathology.
The Journal of urology 1993;150(1):115-9.
1993: E B Miller; L E Ladaga; AM el-Mahdi; Paul F Schellhammer
Reevaluation of prostate biopsy after definitive radiation therapy.
Urology 1993;41(4):311-6.
1993: C L Huang; D Brassil; M Rozzell; Paul F Schellhammer; George L Wright
Comparison of prostate secretory protein with prostate specific antigen and prostatic acid phosphatase as a serum biomarker for diagnosis and monitoring patients with prostate carcinoma.
The Prostate 1993;23(3):201-12.
1992: A M Konchuba; M C Clements; Paul F Schellhammer; Steven M Schlossberg; George L Wright
Failure of anticytokeratin 18 antibody to improve flow cytometric detection of bladder cancer.
Cancer 1992;70(12):2879-84.
1992: A R Brothman; A M Patel; D M Peehl; Paul F Schellhammer
Analysis of prostatic tumor cultures using fluorescence in-situ hybridization (FISH).
Cancer genetics and cytogenetics 1992;62(2):180-5.
1992: C L Huang; H M Liang; D Brassil; Paul F Schellhammer; M Rozzell; K Newhall; ML Beckett; George L Wright
Two-site monoclonal antibody-based immunoradiometric assay for measuring prostate secretory protein in serum.
Clinical chemistry 1992;38(6):817-23.
1992: B M Grob; C Haley; Paul F Schellhammer; Steven M Schlossberg; George L Wright
The detection of prostate specific antigen, MHS-5, and other markers in invasive prostate cancer and seminal vesicle.
The Journal of urology 1992;147(5):1435-8.
1992: Paul F Schellhammer; Gerald H Jordan; E L Robey; J T Spaulding
Premalignant lesions and nonsquamous malignancy of the penis and carcinoma of the scrotum.
The Urologic clinics of North America 1992;19(1):131-42.
1992: G R Eure; M R Cundiff; Paul F Schellhammer
Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
The Journal of urology 1992;147(2):376-9.
1992: D W Brenner; C J Brenner; J Scott; K Wehberg; Joey P Granger; Paul F Schellhammer
Suprarenal Greenfield filter placement to prevent pulmonary embolus in patients with vena caval tumor thrombi.
The Journal of urology 1992;147(1):19-23.
1991: A R Brothman; D M Peehl; A M Patel; G R MacDonald; J E McNeal; L E Ladaga; Paul F Schellhammer
Cytogenetic evaluation of 20 cultured primary prostatic tumors.
Cancer genetics and cytogenetics 1991;55(1):79-84.
1991: Paul F Schellhammer; DA Kuban; AM el-Mahdi
Local failure after definitive radiation or surgical therapy for carcinoma of the prostate and options for prevention and therapy.
The Urologic clinics of North America 1991;18(3):485-99.
1991: Paul F Schellhammer; Steven M Schlossberg; AM el-Mahdi; George L Wright; D N Brassil
Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate.
The Journal of urology 1991;145(5):1008-10; discussion 1010-1.
1991: George L Wright; ML Beckett; Grayson Lipford; C L Haley; Paul F Schellhammer
A novel prostate carcinoma-associated glycoprotein complex (PAC) recognized by monoclonal antibody TURP-27.
International journal of cancer. Journal international du cancer 1991;47(5):717-25.
1991: ML Beckett; Grayson Lipford; C L Haley; Paul F Schellhammer; George L Wright
Monoclonal antibody PD41 recognizes an antigen restricted to prostate adenocarcinomas.
Cancer research 1991;51(4):1326-33.
1991: DA Kuban; Paul F Schellhammer; AM el-Mahdi
Hemibody irradiation in advanced prostatic carcinoma.
The Urologic clinics of North America 1991;18(1):131-7.
1991: Paul F Schellhammer
BCG treatment of superficial transitional cell carcinoma.
Urology 1991;37(5 Suppl):16-8.
1990: Paul F Schellhammer; AM el-Mahdi; DA Kuban
Local failure and related complications after definitive treatment of clinical stage C carcinoma of the prostate by irradiation or surgery.
Seminars in urology 1990;8(4):232-46.
1990: Paul F Schellhammer; AM el-Mahdi
Local failure and related complications after definitive treatment of carcinoma of the prostate by irradiation or surgery.
The Urologic clinics of North America 1990;17(4):835-51.
1990: George L Wright; J P Alexander; A M Konchuba; Paul F Schellhammer; Steven M Schlossberg
Flow cytometric DNA analysis after immunoselection of bladder tumor cells with monoclonal antibody DU83.21.
Cancer 1990;66(6):1242-52.
1990: J P Petersen; Paul F Schellhammer; AM el-Mahdi
Disease-related effects of perioperative blood transfusions associated with 125I seed implantation for prostate carcinoma.
Urology 1990;36(2):103-6.
1990: D W Brenner; L E Ladaga; M B Fillion; Steven M Schlossberg; Paul F Schellhammer
Comparison of transrectal fine-needle aspiration cytology and core needle biopsy in diagnosis of prostate cancer.
Urology 1990;35(5):381-4.
1989: D W Brenner; M A Fogle; Paul F Schellhammer
Venous thromboembolism.
The Journal of urology 1989;142(6):1403-11.
1989: D W Brenner; L M Yore; Paul F Schellhammer
Squamous cell carcinoma of bladder after successful intravesical therapy with Bacillus Calmette-Guérin.
Urology 1989;34(2):93-5.
1989: DA Kuban; AM el-Mahdi; Paul F Schellhammer
Prognosis in patients with local recurrence after definitive irradiation for prostatic carcinoma.
Cancer 1989;63(12):2421-5.
1989: DA Kuban; AM el-Mahdi; Paul F Schellhammer
I-125 interstitial implantation for prostate cancer. What have we learned 10 years later?
Cancer 1989;63(12):2415-20.
1989: R B Whitmore; Paul F Schellhammer
Giant hydronephrosis of a duplex system associated with ureteral ectopia.
The Journal of urology 1989;141(5):1186-8.
1989: Paul F Schellhammer; R B Whitmore; DA Kuban; AM el-Mahdi; L A Ladaga
Morbidity and mortality of local failure after definitive therapy for prostate cancer.
The Journal of urology 1989;141(3):567-71.
1989: DA Kuban; T Delbridge; AM el-Mahdi; Paul F Schellhammer
Half-body irradiation for treatment of widely metastatic adenocarcinoma of the prostate.
The Journal of urology 1989;141(3):572-4.
1989: A M Konchuba; Paul F Schellhammer; J P Alexander; George L Wright
Flow cytometric study comparing paired bladder washing and voided urine for bladder cancer detection.
Urology 1989;33(2):89-96.
1989: A R Brothman; L J Lesho; Kenneth D Somers; Paul F Schellhammer; L E Ladaga; D J Merchant
Cytogenetic analysis of four primary prostatic cultures.
Cancer genetics and cytogenetics 1989;37(2):241-8.
1989: DA Kuban; AM el-Mahdi; Paul F Schellhammer
Mortality in prostatic carcinoma.
Urology 1989;33(1):1-5.
1988: S K Blackley; L Ladaga; R A Woolfitt; Paul F Schellhammer
Ex situ study of the effectiveness of enucleation in patients with renal cell carcinoma.
The Journal of urology 1988;140(1):6-10.
1988: Paul F Schellhammer
Radical prostatectomy. Patterns of local failure and survival in 67 patients.
Urology 1988;31(3):191-7.
1988: R W Hillyard; L Ladaga; Paul F Schellhammer
Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin.
The Journal of urology 1988;139(2):290-3.
1987: DA Kuban; AM el-Mahdi; Paul F Schellhammer
Effect of local tumor control on distant metastasis and survival in prostatic adenocarcinoma.
Urology 1987;30(5):420-6.
1987: D W Brenner; Paul F Schellhammer
Mortality associated with feeding catheter jejunostomy after radical cystectomy.
Urology 1987;30(4):337-40.
1987: Paul F Schellhammer; AM el-Mahdi; E M Higgins; Timothy Schultheiss; L E Ladaga; T J Babb
Prostate biopsy after definitive treatment by interstitial 125iodine implant or external beam radiation therapy.
The Journal of urology 1987;137(5):897-901.
1986: Paul F Schellhammer; L E Ladaga; M B Fillion
Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.
The Journal of urology 1986;135(2):261-4.
1982: George L Wright; Paul F Schellhammer; Mary S Leffell; S M Sieg; B N Brassil
Radioimmunoassay versus counterimmune electrophoresis for measurement of serum prostatic acid phosphatase.
Urology 1982;19(4):351-5.
1981: George L Wright; Paul F Schellhammer; D N Brassil; S M Sieg; Mary S Leffell
Comparison of countercurrent immunoelectrophoretic assay with commercial radioimmunoassay kits for measuring prostatic acid phosphatase.
Clinical chemistry 1981;27(10):1747-52.
1981: George L Wright; Paul F Schellhammer; R J Faulconer; J W Reid; D N Brassil; S M Sieg
Leukocyte migration inhibition assay in patients with prostate adenocarcinoma.
The Prostate 1981;2(2):121-31.